Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 2, 2014, Pages 457-462

  Arsenault, Benoit J ^a,b   Dubé, Marie Pierre ^a,b   Brodeur, Mathieu R ^a,b   De Oliveira Moraes, Adriana Benjamin ^a,b   Lavoie, Véronique ^a   Kernaleguen, Anne Elen ^a   Guauque Olarte, Sandra ^c   Mathieu, Patrick ^c   Pibarot, Philippe ^c   Messika Zeitoun, David ^e,f   Bossé, Yohan ^c,d   Rhainds, David ^a   Rhéaume, Éric ^a,b   Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e BICHAT HOSPITAL   (France)

^f INSERM   (France)

Author keywords

aortic valve stenosis; cholesterol efflux capacities; coronary artery disease; high density lipoproteins; human genetics

Indexed keywords

AORTIC VALVE STENOSIS; CHOLESTEROL EFFLUX CAPACITIES; CORONARY ARTERY DISEASE; HIGH-DENSITY LIPOPROTEINS; HUMAN GENETICS;

AGED; ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MACROPHAGES; MALE; MICE; MIDDLE AGED; PARIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUEBEC; RISK FACTORS;

EID: 84895032730     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302730     Document Type: Article

References (24)

1. Iung B, Vahanian A. Degenerative calcific aortic stenosis: A natural history. Heart. 2012;98(Suppl 4):iv7-13
2. Passik CS, Ackermann DM, Pluth JR, Edwards WD. Temporal changes in the causes of aortic stenosis: A surgical pathologic study of 646 cases. Mayo Clin Proc. 1987;62:119-123
3. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630-634
4. Probst V, Le Scouarnec S, Legendre A, Jousseaume V, Jaafar P, Nguyen JM, Chaventré A, Le Marec H, Schott JJ. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation. 2006;113:856-860
5. Le Gal G, Bertault V, Bezon E, Cornily JC, Barra JA, Blanc JJ. Heterogeneous geographic distribution of patients with aortic valve stenosis: Arguments for new aetiological hypothesis. Heart. 2005;91:247-249
6. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-274
7. Gaudreault N, Ducharme V, Lamontagne M, Guauque-Olarte S, Mathieu P, Pibarot P, Bossé Y. Replication of genetic association studies in aortic stenosis in adults. Am J Cardiol. 2011;108:1305-1310
8. Thanassoulis G, Campbell CY, Owens DS, et al CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-512
9. Lommi JI, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Kupari M, Helske S. High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis. 2011;219:538-544
10. Busseuil D, Shi Y, Mecteau M, Brand G, Kernaleguen AE, Thorin E, Latour JG, Rhéaume E, Tardif JC. Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol. 2008;154:765-773
11. Trapeaux J, Busseuil D, Shi Y, Nobari S, Shustik D, Mecteau M, El-Hamamsy I, Lebel M, Mongrain R, Rhéaume E, Tardif JC. Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice. Br J Pharmacol. 2013;169:1587-1599
12. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, Fuster V, Goldman ME, Badimon JJ. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J. 2010;31:2049-2057
13. Katz R, Budoff MJ, Takasu J, Shavelle DM, Bertoni A, Blumenthal RS, Ouyang P, Wong ND, O'Brien KD. Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes. 2009;58:813-819
14. Swierszcz J, Dubiel JS, Milewicz T, Sztefko K, Krzysiek J. [Smoking, increase in plasma lipoprotein (a) and triglycerides, as well as decrease in plasma HDL-cholesterol concentrations seem to be linked with aortic valve stenosis and its progression]. Przegl Lek. 2009;66:159-165
15. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135
16. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet. 2012;380:572-580
17. Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002;91:570-576
18. Mohty D, Pibarot P, Després JP, Cartier A, Arsenault B, Picard F, Mathieu P. Age-related differences in the pathogenesis of calcific aortic stenosis: The potential role of resistin. Int J Cardiol. 2010;142:126-132
19. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696-1705
20. deGoma EM, Degoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199-2211
21. Geng Y, Hsu JJ, Lu J, Ting TC, Miyazaki M, Demer LL, Tintut Y. Role of cellular cholesterol metabolism in vascular cell calcification. J Biol Chem. 2011;286:33701-33706
22. Wang H, Goland S, Burton K, Czer LS, Schwarz ER, Trento A. An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model. J Heart Valve Dis. 2010;19:653-664
23. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT. High pre-beta1 HDL concentrations and low lecithin: Cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56:1128-1137
24. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via abca1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801